Related Experiment Videos
Etoposide (VP-16): cytogenetic studies in mice
K Agarwal1, A Mukherjee, S Sen
1Centre for Advanced Study in Cell and Chromosome Research, University of Calcutta, India.
Environmental and Molecular Mutagenesis
|January 1, 1994
Summary
Etoposide, a cancer drug, causes DNA damage and genetic mutations in mice. This study confirms its clastogenic and genotoxic effects in vivo, highlighting its S-phase cell specificity.
Area of Science:
- Pharmacology
- Genetics
- Toxicology
Background:
- Etoposide (VP 16-213) is an epipodophyllotoxin derivative used in cancer therapy.
- It exerts cytotoxicity by forming complexes with DNA-topoisomerase type II alpha.
Purpose of the Study:
- To evaluate the in vivo genotoxicity of etoposide in Swiss albino mouse bone marrow cells.
- To assess its potential to induce clastogenicity and sister chromatid exchanges (SCEs).
Main Methods:
- Intraperitoneal administration of etoposide at various doses (0.5-20 mg/kg).
- Analysis of bone marrow cells for chromosomal aberrations and SCEs.
- Cell cycle analysis to determine drug-induced delays.
Main Results:
- Etoposide induced a dose-dependent increase in clastogenicity and SCEs.
- The drug demonstrated S-phase cell specificity, with peak effects observed 6-12 hours post-treatment.
- Etoposide significantly prolonged cell cycle time in a dose-dependent manner.
Conclusions:
- Etoposide is a potent in vivo clastogen and genotoxic agent in mice.
- The findings confirm the drug's cell cycle phase specificity.
- Etoposide's genotoxic potential warrants consideration in clinical applications.